Hugh O'Dowd
Chairman bei ONK Therapeutics Ltd.
Vermögen: 278 615 $ am 31.03.2024
Profil
Hugh O'Dowd currently works at ONK Therapeutics Ltd., as Independent Non-Executive Chairman from 2021.
Mr. O'Dowd also formerly worked at TherapeuticsMD, Inc., as President, Chief Executive Officer & Director from 2021 to 2022, BioNTech US, Inc., as President, Chief Executive Officer & Director from 2016 to 2020, Spexis Ltd., as Director, Puma Biotechnology, Inc., as Independent Director from 2019 to 2021, Novartis Oncology, Inc., as Chief Commercial Officer & Head-Global Strategy from 2011 to 2015, Novartis UK Ltd., as President & General Manager from 2015 to 2016, Novartis Ireland Ltd., as President & General Manager from 2015 to 2016, and Novartis International Pharmaceutical Ltd., as General Manager from 2015 to 2016.
Mr. O'Dowd received his undergraduate degree from Loyola University of Chicago and Masters Business Admin degree from Kellstadt Graduate School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
THERAPEUTICSMD, INC.
1,15% | 20.04.2023 | 121 666 ( 1,15% ) | 278 615 $ | 31.03.2024 |
Aktive Positionen von Hugh O'Dowd
| Unternehmen | Position | Beginn |
|---|---|---|
ONK Therapeutics Ltd.
 ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Chairman | 14.01.2021 |
Ehemalige bekannte Positionen von Hugh O'Dowd
| Unternehmen | Position | Ende |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Director/Board Member | 15.06.2021 |
| NEON THERAPEUTICS, INC. | Chief Executive Officer | 06.05.2020 |
Novartis UK Ltd.
 Novartis UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis UK Ltd. is an international pharmaceutical company. It strives to discover ways to improve and extend people’s lives. The company is headquartered in Frimley, the United Kingdom. | President | 01.01.2016 |
Novartis International Pharmaceutical Ltd.
 Novartis International Pharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Novartis International Pharmaceutical Ltd. manufactures and distributes pharmaceutical products. The company is headquartered in Ireland. | Corporate Officer/Principal | 01.01.2016 |
| Novartis Ireland Ltd. | President | 01.01.2016 |
Ausbildung von Hugh O'Dowd
| Loyola University of Chicago | Undergraduate Degree |
| Kellstadt Graduate School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SPEXIS AG | Health Technology |
| THERAPEUTICSMD, INC. | Health Technology |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Novartis UK Ltd.
Novartis UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis UK Ltd. is an international pharmaceutical company. It strives to discover ways to improve and extend people’s lives. The company is headquartered in Frimley, the United Kingdom. | Health Technology |
| Novartis Ireland Ltd. | |
Novartis International Pharmaceutical Ltd.
Novartis International Pharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Novartis International Pharmaceutical Ltd. manufactures and distributes pharmaceutical products. The company is headquartered in Ireland. | Health Technology |
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Health Technology |
